Activity update up to October 2018

New partnership with Novartis to reduce child deaths from drug-resistant infections

[Basel, Geneva – 27 September 2018]

GARDP and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries. The strategic partnership responds to the call from the World Health Organization for affordable, improved, and adapted antibiotic formulations and regimens for this vulnerable population, for which treatment options are limited.


Researchers in New Delhi kick off study of newborns with sepsis

[New Delhi/Geneva – 3 July 2018]

Study aims to guide development of new treatments and reverse global increase in deaths of newborns

Over 80 researchers from 11 countries are meeting in New Delhi today to kick off an observational study to understand sepsis in newborns and current antibiotic prescribing practices. The observational study, led by GARDP, is benefiting from US$2 million funding from Bill & Melinda Gates Foundation.


Presentation of GARDP by Dr Manica Balasegaram, Executive Director

Register for upcoming webinars on antimicrobial drug development and catch-up on those you may have missed

REVIVE is an online space for the antimicrobial R&D community to educate, connect, and share good practice in how to conduct antimicrobial drug R&D. It facilitates exchanges between clinical and non-clinical researchers with world-class experts active in antimicrobial R&D over the last 40 years. So far, more than 100 experts have engaged with REVIVE.